VolitionRx (VNRX) Projected to Post Quarterly Earnings on Monday

VolitionRx (NYSEAMERICAN:VNRX) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.55 million for the quarter.

VolitionRx Stock Down 3.6 %

VNRX opened at $0.56 on Monday. The stock has a market capitalization of $35.45 million, a PE ratio of -1.00 and a beta of 1.59. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.02.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.